Brief: Tempus Announces Strategic Collaboration With Daiichi Sankyo To Advance Ai-Driven Biomarker Discovery And Clinical Differentiation Across An Adc Clinical Program
25/03/2026 12:56
Daiichi Sankyo Co Ltd 4568.T: TEMPUS ANNOUNCES STRATEGIC COLLABORATION WITH DAIICHI SANKYO TO ADVANCE AI-DRIVEN BIOMARKER DISCOVERY AND CLINICAL DIFFERENTIATION ACROSS AN ADC CLINICAL PROGRAM TEMPUS AI : DAIICHI SANKYO WILL LEVERAGE TEMPUS' PROPRIETARY FOUNDATION MODELS AND AI EXPERTISE, INCLUDING PRISM2 MULTIMODAL FOUNDATION MODEL Source text: ID:nBw308dwRa Further company coverage: 4568.T